Erenumab For Treatment of Hemicrania Continua

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Antibodies, Monoclonal; Erenumab

Criteria

Inclusion Criteria

• Adults over the age of 18-66

• At least a 12 month history of hemicrania continua (unremitting subtype) according to International Classification of Headache Disorders, 3rd Edition (ICHD-3)1

• Previous or current complete response to indomethacin

• Stable preventive treatment for at least 2 months and no anticipated need to adjust/add current headache prevention treatment

Exclusion Criteria

• Nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used for at least 1 week

• Pregnant or lactating subjects

• Use of barbiturate or opioid >6 days per month; history of chronic migraine

• History of previous trigeminal-autonomic cephalalgia

• History within previous 2 months of interventional procedure for headache (occipital or other extracranial nerve block, sphenopalatine ganglion block, cervical facet block, facet rhizotomy)

• History of cranial nerve/rhizolysis

• Botulinumtoxin injection with previous 4 months

• Parenteral infusion of or oral corticosteroid use for more than 3 days within 4 weeks prior to screening phase